Hope for primary cardiovascular prevention with the HOPE (Heart Outcomes Prevention Evaluation)-3 trial findings
DOI:
https://doi.org/10.21542/gcsp.2016.13Abstract
The HOPE-3 investigators enrolled 12,705 intermediate-risk participants in 21 countries in a 2-by-2 factorial trial. Subjects were randomized to receive a fixed dose of rosuvastatin or placebo, candesartan plus hydrochlorothiazide daily or placebo, and a third group received combination of antihypertensive and statins versus double placebo. The median follow-up was 5.6 years. The combination of antihypertensive and statin therapy was associated with a significantly lower rate of cardiovascular events than dual placebo. Statin therapy alone was also associated with improved outcome, while antihypertensive therapy had no added benefit compared to placebo.
Downloads
Published
Issue
Section
License
This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.